BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DR-0202 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DR-0202\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06999187-2459@assetmemo.bio
DTSTAMP:20261121T005427Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:DR-0202: Phase 1 readout est. (NCT06999187)
DESCRIPTION:DR-0202\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study
  of DR-0202 in Patients With Locally Advanced or Metastatic\, Relapsed or 
 Refractory Carcinomas\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dr-0202#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06999187
URL:https://assetmemo.bio/drug/dr-0202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
